Clinical trial
Pilot Study of the Effect of Adalimumab on Physical Function and Musculoskeletal Disease in Mucopolysaccharidosis Types I, II and VI
NCT02437253 is registered in ClinicalTrials.gov with Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Pilot Study of the Effect of Adalimumab on Physical Function and Musculoskeletal Disease in Mucopolysaccharidosis Types I, II and VI
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- May 31, 2015
- Completion date
- July 31, 2016
- Enrollment
- 2 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
mucopolysaccharidosis type i, mucopolysaccharidosis type ii, mucopolysaccharidosis type vi